VKTX240816C22000
- 34.80
- +5.30+17.97%
Viking Therapeutics Newsroom
Buy Rating on Viking Therapeutics: Promising VK2735 Development and Strategic Advancements
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Vericel (VCEL)
Truist Financial Keeps Their Buy Rating on Viking Therapeutics (VKTX)
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $105 to $138
Buy Rating Affirmed on Viking Therapeutics as Key Drug Advances to Phase 3 Trials
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $138
Viking Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Viking Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Day One Biopharmaceuticals (DAWN)
Truist Financial Releases a Buy Rating on Viking Therapeutics (VKTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
Viking Therapeutics Analyst Ratings
Viking Therapeutics Analyst Ratings
Viking Therapeutics Analyst Ratings